Free Trial
→ Trump wipes out trillions overnight… (From Porter & Company) (Ad)
NYSEAMERICAN:AZTR

Azitra 8/12/2024 Earnings Report

Azitra logo
$0.27 -0.01 (-2.14%)
As of 02:39 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.
ProfileEarnings History

Azitra EPS Results

Actual EPS
-$2.74
Consensus EPS
-$2.59
Beat/Miss
Missed by -$0.15
One Year Ago EPS
N/A

Azitra Revenue Results

Actual Revenue
$0.01 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Azitra Announcement Details

Quarter
Date
8/12/2024
Time
TAS
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Azitra's next earnings date is estimated for Monday, August 11, 2025, based on past reporting schedules.

Conference Call Resources

Azitra Earnings Headlines

Azitra, Inc. Announces Presentation at ASCO 2025 Highlighting Clinical Trial Investigating ATR-04 for EGFRi-Associated Rash
May 28 at 8:33 AM | prnewswire.com
FY2025 EPS Estimates for Azitra Lifted by Zacks Small Cap
May 24, 2025 | americanbankingnews.com
Gold Hits New Highs as Global Markets Spiral
When Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. Now… as new tariffs take effect, gold is breaking records again. You've hopefully already seen this in action… but gold is surpassing $3,000 per ounce for the first time EVER.
May 29, 2025 | Premier Gold Co (Ad)
Q2 Earnings Forecast for Azitra Issued By Zacks Small Cap
May 24, 2025 | americanbankingnews.com
AZTR: ATR-04 Trial to Dose 1st Patient Mid-2025
May 21, 2025 | finance.yahoo.com
Azitra, Inc. to Present Abstract at American Society of Gene and Cell Therapy Highlighting Phase 1/2 Study Targeting Cancer Therapy-Associated Rash
May 14, 2025 | prnewswire.com
See More Azitra Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Azitra? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Azitra and other key companies, straight to your email.

About Azitra

Azitra (NYSEAMERICAN:AZTR), an early-stage biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It develops ATR-12, a genetically modified strain of S. epidermidis, which is in Phase Ib clinical trial for treating Netherton syndrome, a skin disease. The company also develops ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor; and ATR-01, an engineered recombinant human filaggrin protein for treating ichthyosis vulgaris, a skin disease. It has a collaboration with Bayer. The company was incorporated in 2014 and is based in Branford, Connecticut.

View Azitra Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles